<DOC>
	<DOCNO>NCT00483197</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness VentrAssistTM LVAD individual await heart transplant .</brief_summary>
	<brief_title>VentrAssistTM LVAD Bridge Cardiac Transplantation - Pivotal Trial</brief_title>
	<detailed_description>LVADs efficacious improve survival functional status use bridge transplantation . The purpose study evaluate safety effectiveness VentrAssist LVAD provide circulatory support individual await heart transplant . The VentrAssist LVAD centrifugal flow pump . Its small size mechanical simplicity offer benefit available currently approve LVADs , include facilitate limited implantation procedure , could reduce surgical morbidity mortality .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>( The follow general criterion ; specific criterion include study protocol ) : Approved listed cardiac transplantation . Patient LVAD implantation plan clinically indicate bridge cardiac transplantation . ( The follow general criterion ; specific criterion include study protocol ) : Presence heart condition would contraindicate LVAD implantation adversely affect patient survival LVAD function . Primary coagulopathy platelet disorder ; contraindication anticoagulant antiplatelet agent . Presence mechanical circulatory support intraaortic balloon pump . Therapy investigational intervention time screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>VentrAssistTM</keyword>
	<keyword>LVAD</keyword>
	<keyword>End-stage heart failure</keyword>
	<keyword>Cardiomyopathy</keyword>
</DOC>